Clinical Trial Update: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating natalizumab for reducing disability progression in secondary progressive multiple sclerosis; study terminated with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Secondary Progressive Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2017-06-27